Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) (NCT04292899), a randomized phase 3 study. The primary outcome is Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 14.

2. Clinical Question

3. Trial Design

This was a randomized, open-label, parallel-group phase 3 study sponsored by Gilead Sciences. The registry lists an enrollment of 4891 and a completed status. The study start date was 2020-03-06, and the primary completion date was 2020-04-09. These registry dates and the overall enrollment do not establish how many participants contributed to the primary Part A analysis.

Part A included remdesivir regimens lasting 5 days or 10 days, each alongside continued standard of care. The 5-day regimen specified 200 mg on Day 1 followed by 100 mg on Days 2, 3, 4, and 5. The 10-day regimen specified 200 mg on Day 1 followed by 100 mg on Days 2 through 10. The primary objective was to evaluate the regimens with respect to clinical status assessed using a 7-point ordinal scale on Day 14.

The registry also describes Part B groups: an extension group and a mechanically ventilated group, both assigned a 10-day remdesivir regimen with continued standard of care. The extension was to enroll after Part A enrollment was complete. The registry’s primary outcome population, however, is specifically defined as participants randomized into Part A who received at least 1 dose. Part B safety counts should therefore not be treated as additional participants in the primary Part A comparison.

No masking was used. The record does not report the randomization ratio, allocation concealment procedures, site count, detailed eligibility criteria, or the exact numbers randomized to each Part A group for the primary analysis. Those details cannot be inferred from the overall enrollment.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: 4958 participants were screened. 4891 participants were enrolled. 4 participants in Part A and 49 participants in Part B did not receive treatment and are not included in the analyses.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Full Analysis Set included participants who were randomized into part A of the study and received at least 1 dose of study treatment.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Part A: Safety Analysis Set included participants who were randomized into part A of the study and received at least 1 dose of study treatment. Part B: Expanded RDV-Treated Analysis Set included participants who were enrolled into part B of the study and received at least 1 dose of study treatment.

6. Primary Endpoint

The registry lists the primary outcome as Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 14, measured over Day 14.

The primary outcome was the percentage of participants in each clinical status category on Day 14, measured with a 7-point ordinal scale. Its categories run from death, through hospitalization with different levels of respiratory support or care, to not hospitalized. The scale therefore represents ordered clinical states rather than a single binary event.

In general, an ordinal endpoint can retain distinctions across several levels of status instead of reducing them to a simple event/no-event outcome. That can make it useful when an intervention may be associated with shifts across multiple degrees of clinical condition. The registry defines improvement as the direction represented in its odds-ratio comparison: odds for the 10-day group versus the 5-day group. The statistical model and the specific estimation procedure are not reported in the registry record.

The outcome definition assigns a score of 1 on and after the date of death, and a score of 7 on and after discharge alive. For missing values, it carries the last assessment forward. These rules affect how day-specific status is represented. The registry record describes the endpoint but does not report the percentages in the individual categories, an overall effect estimate, or its uncertainty. As a result, the endpoint’s intended comparison can be described, but the observed primary result cannot be quantified from the reported information.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The study is described as randomized, open-label, and parallel group. Randomization is generally used to make treatment groups comparable, on average, with respect to both measured and unmeasured factors at assignment. It does not guarantee identical groups in a particular trial. Open-label means the registry lists no masking; the record does not describe procedures to reduce possible effects of treatment awareness on care, outcome assessment, or reporting.

What does the ordinal outcome represent?

The primary measure classifies clinical status on a 7-point scale on Day 14. Its levels have a natural order, from death at the low end to not hospitalized at the high end, with distinctions among hospitalized participants in between. In general, an ordinal scale preserves more information than collapsing all participants into two broad groups. At the same time, a single summary effect can conceal how results differ across individual categories. The registry describes an odds ratio for improvement but does not report the model, the category-specific counts, or the estimated odds ratio.

The outcome rules also matter. A score of 1 is used on and after the date of death, and a score of 7 on and after the date of discharge alive. For missing assessments, the last assessment is carried forward. In general, carrying the last observed value forward assumes that it is an appropriate substitute for the missing value at the outcome time. If status changes after the last assessment, that substitution may not reflect the participant’s actual status on Day 14. The registry does not report how many values were missing or whether other missing-data analyses were conducted.

How should an odds ratio be read?

In general, an odds ratio compares odds between groups, with the interpretation depending on the event or direction being modeled and the model’s assumptions. Here, the registry specifically defines the comparison as the odds of improvement for the 10-day group versus the 5-day group. That definition sets the direction of the contrast, but without the estimate and its confidence interval there is no reported magnitude or precision to interpret. The analysis method, adjustment variables, and handling of the ordinal categories in the model are not reported in the registry record.

What do the planning illustrations mean?

Any sample-size illustrations associated with the posted analysis are planning calculations based on a stated fraction of the observed effect, a two-sided significance level of 0.05, equal allocation, and a normal approximation. For non-time-to-event outcomes, such illustrations are expressed as participants per arm for a specified power. They are not the trial’s original sample-size justification and are not observed power. In general, such calculations describe the sample size that would be needed under the chosen assumptions to detect a selected effect. They do not establish that the trial was designed around those assumptions. The registry record does not report the original sample-size justification, its target effect, or its design assumptions.

More broadly, the registry record does not report whether interim analyses were planned or performed, the statistical analysis plan, the model diagnostics, or sensitivity analyses for the primary endpoint. Without this information, readers cannot assess whether the reported outcome definition and analysis choices were fully prespecified or how robust conclusions would be to alternative methods. The record lists 3 analyses, but their details are not reported in the registry record.

10. Multiplicity, Missing Data and Analysis Populations

The primary outcome has several clinical-status categories, and the study also lists a secondary outcome: the percentage of Part A participants who experienced treatment-emergent adverse events. The registry record does not report a multiplicity procedure, such as an adjustment to account for testing multiple outcomes or comparisons. It also does not specify whether the secondary outcome was intended to support confirmatory inference or to describe safety. Without a reported plan, the interpretation of any individual p-value across multiple analyses would be uncertain; in any case, no primary-outcome p-value is reported.

Missing data are addressed in the primary outcome definition by carrying the last assessment forward. The rules also assign the lowest category on and after death and the highest category on and after discharge alive. The registry does not report how many Day 14 assessments were missing, how many participants were excluded from the primary analysis, or whether sensitivity analyses were used to evaluate the effect of the missing-data rule. In general, imputation or carry-forward methods rely on assumptions about what unobserved outcomes would have been. The reported rule alone does not establish how well those assumptions fit these data.

The primary analysis population is defined as the Full Analysis Set, including participants randomized into Part A who received at least 1 dose of study treatment. The registry does not report the resulting analysis count by treatment group or explain the handling of participants who were randomized but did not receive treatment. It also does not report whether a separate intention-to-treat analysis was conducted. The total enrollment of 4891 includes a broader study record and cannot be taken as the primary endpoint denominator.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: acute respiratory failure (9.1%), respiratory failure (7.1%), acute kidney injury (5.9%), corona virus infection (5.1%), multiple organ dysfunction syndrome (3.2%).

The registry lists serious adverse events by study group as counts of participants at risk and participants affected. In Part A, the 5-day group had 200 participants at risk and 43 affected; the 10-day group had 197 at risk and 68 affected. In Part B, the mechanically ventilated group had 844 at risk and 362 affected, while the extension group had 3597 at risk and 851 affected. These are separate groups and should be read in the context of their different study parts and populations.

The record also lists other adverse-event counts and deaths for each group. The serious-event, other-event, and death figures should not be assumed to be mutually exclusive categories: a participant may contribute to more than one reported category. The registry does not describe how events were adjudicated, their timing, or whether investigators considered them related to treatment.

The most frequent listed serious-event terms include acute respiratory failure at 9.1%, respiratory failure at 7.1%, acute kidney injury at 5.9%, and corona virus infection at 5.1%. Multiple organ dysfunction syndrome and septic shock are each listed at 3.2%. These percentages are descriptive entries; the record does not provide the denominators or additional detail needed to interpret them as comparative risks. Counts across Part A and Part B should not be pooled or compared as if the groups had the same clinical composition.

12. What the Result Does, and Does Not, Mean

The registry record establishes that the study was designed to compare two remdesivir treatment durations alongside standard of care, with Day 14 clinical status as the primary endpoint. It also provides the ordinal scale definition, the population definition, and selected adverse-event counts. These details clarify what the study set out to assess and how the primary outcome was constructed.

They do not establish the result of the primary comparison. The category-specific Day 14 percentages, the odds-ratio estimate, and measures of uncertainty are not reported in the registry record. It is therefore not possible to describe which group had better observed clinical status, how large any difference was, or how precisely it was estimated. Missing estimates should not be interpreted as evidence of no difference.

The adverse-event counts describe events recorded in the listed groups. They do not by themselves establish that an event was caused by remdesivir, and they do not provide a direct comparison of treatment-related harm between groups. Group populations differ by study part, and the registry does not report enough detail about event attribution, timing, or statistical comparison to support stronger conclusions.

In general, interpretation of a randomized trial also depends on the analysis population, outcome ascertainment, missing-data methods, and prespecified statistical plan. The record gives some outcome rules but does not report the primary analysis estimate, detailed analysis methods, multiplicity approach, or a full account of missing data. Those gaps limit independent assessment of both effect and robustness.

The appropriate reading is consequently narrow: the registry describes the trial question and some safety observations, but the posted results available in this record do not permit a quantitative assessment of the primary efficacy comparison. No treatment recommendation follows from these registry entries alone.

13. Why This Trial Matters Statistically

This trial is statistically notable for a design question that is easy to misread: the primary comparison was between 5-day and 10-day remdesivir regimens, with both groups receiving continued standard of care. It was not defined as remdesivir versus no remdesivir. Keeping the comparator clear is essential to interpreting what the study could estimate.

The primary endpoint also illustrates a common clinical-trial choice. A 7-point ordinal scale retains distinctions across several levels of clinical status rather than reducing the outcome to a single event. That can represent a broader range of patient states, but it makes transparent reporting of category distributions and the analysis method especially important. The registry defines the scale and says the odds ratio concerns improvement, yet does not report the estimated comparison or the category percentages.

The record also illustrates why overall enrollment and analysis population are not interchangeable. Although enrollment is listed as 4891, the primary outcome population is defined only as Part A randomized participants who received at least 1 dose. The number analyzed in that population is not reported. Part B safety groups are separately described and should not be used to fill that gap.

Finally, the safety counts show why study-part context matters. The listed groups vary substantially in size and include a mechanically ventilated group and an extension group. Descriptive counts from such groups do not automatically form a valid comparative analysis. For statistical readers, the central lesson is to distinguish the study question and descriptive record from an estimated treatment effect: the latter requires results and uncertainty that are not reported.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation for interpreting efficacy is that the registry record does not report the primary outcome results by category, an odds-ratio estimate, a confidence interval, or a p-value. The study question and endpoint are described, but the size and precision of the treatment contrast cannot be assessed.

The primary population is defined as Part A participants who were randomized and received at least 1 dose. The number analyzed, group-specific denominators, and reasons for any exclusions are not reported. The overall enrollment of 4891 does not resolve this, because the study also includes Part B groups and the primary outcome population is specifically limited to Part A.

The record specifies last assessment carried forward for missing values and assigns scores after death or discharge. It does not report the amount of missing data or sensitivity analyses. The statistical model for the ordinal outcome, adjustment strategy, multiplicity plan, interim analyses, and original sample-size justification are also not reported in the registry record.

For safety, counts are given across distinct study groups, but the record does not provide event timing, attribution to treatment, or a comparative analysis. Serious-event term percentages are listed without enough accompanying detail to assess their denominators or compare them across groups. The open-label design is recorded, but the consequences for outcome assessment or care cannot be evaluated from the information reported.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) — NCT04292899.
• Registry record last updated 2020-12-31; status last verified 2020-12.
• Results first posted 2020-12-31.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

This completed, randomized, open-label, parallel-group phase 3 study was sponsored by Gilead Sciences and concerned severe COVID-19. The registry lists enrollment of 4891, a start date of 2020-03-06, and a primary completion date of 2020-04-09.

The primary objective was to evaluate 5-day and 10-day remdesivir regimens, each alongside continued standard of care, using clinical status on Day 14. The outcome was a 7-point ordinal scale, and the primary population was Part A participants randomized and treated with at least 1 dose.

The record describes Part B extension and mechanically ventilated groups and lists safety counts across the study groups. It does not report the primary category percentages or the estimated odds ratio and its uncertainty. Detailed statistical methods, the original sample-size justification, and the multiplicity plan are not reported in the registry record.